MacroGenics Enters Agreement With TerSera Therapeutics, Under Which TerSera Will Acquire Global Rights To MARGENZA; TerSera To Pay MacroGenics $40M At Closing And MacroGenics May Receive Milestones Up To $35M
Portfolio Pulse from Benzinga Newsdesk
MacroGenics has entered into an agreement with TerSera Therapeutics, where TerSera will acquire global rights to MARGENZA. MacroGenics will receive $40 million at closing and may receive up to $35 million in milestone payments.
October 22, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MacroGenics has sold the global rights to its product MARGENZA to TerSera Therapeutics for $40 million upfront, with potential additional milestone payments of up to $35 million. This deal could positively impact MacroGenics' financials.
The sale of MARGENZA rights provides immediate cash inflow of $40 million and potential future milestone payments, which could strengthen MacroGenics' financial position and support its operations or other projects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100